Press releases

New article | Microbiota influences chemotherapy in pancreatic cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)

New article | Parkinson's Disease analysed via brain organoids

| Oct 2021 | In a study led by University of Luxembourg and OrganoTherapeutics SARL-S we used our scioPhospho assay to analyse the reaction of a brain organoid model for Parkinson's disease to certain treatments.

Jarazo, J. et al. (2021) ‘Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxy...’, Movement Disorders, in press: doi: 10.1002/mds.28810 (Please get in touch for fulltext).

 

New article | Biomarker identification and verification in endometriosis

| 22th Oct 2021 | Scientists at University Medical Centre Ljubljana used our scioDiscover platform for a biomarker identification in endometriosis:

"Discovery proteomics using antibody microarrays that covered 1360 proteins identified 16 proteins with different levels in cases versus the control patients. The validation using an ELISA approach confirmed significant differences in the levels of cartilage oligomeric matrix protein (COMP) and transforming growth factor-β-induced protein ig-h3 (TGFBI) and nonsignificant differences in angiotensinogen (AGT). "

 Janša, V. et al. (2021) ‘Proteomic analysis of peritoneal fluid identified COMP and TGFBI as new candidate biomarkers for endometriosis’, Scientific Reports, 11:20870. doi: 10.1038/s41598-021-00299-2. 

biomarkers in endometriosis

 

New article | BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

| Dec 2020 | Scientists at University of Sassari used our scioPhospho  platform to to analyse the synergy of BET and PARP inhibition in Small Cell Lung Cancer Cells:

"Among the I-BET762-associated and combination-associated differentially expressed proteins, 150 were common to both treatment conditions. ... Ranking I-BET762-associated and combination-associated DEPs by their differential expression revealed CHEK2 and PTEN to be among the top-downregulated proteins, whose deficiencies have been associated with HR defects and increased PARPi sensitivity. "

Fiorentino, F. P. et al. (2020) ‘BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells’, International Journal of Molecular Sciences, 21(24). doi: 10.3390/ijms21249595.